Pharmaceutical Executive June 1, 2023

Bloomberg Intelligence survey credits increased medication access for potential spike.

According to a report by Bloomberg Intelligence, global obesity medication sales could reach $44 billion by 2030, up from $2.5 billion in 2022. Reportedly, analysts believe this will be the result of increased supply, growing demand, and further product innovation.

The organization also credits Novo Nordisk’s Wegovy and Eli Lilly’s tirzepatide with beginning the trend in an out-of-pocket market.

“Unprecedented demand in obesity coupled...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech, Survey / Study, Trends
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Walgreens Suffers $6 Billion Loss As VillageMD Clinic Investment Sours

Share This Article